Idioma:

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L

Scientific reports, 2020-12, Vol.10 (1), p.22370-13, Article 22370 [Revista revisada por pares]

England: Nature Publishing Group

Texto completo disponible

Citas Citado por

Acciones

Título:
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Autor: Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L
Materias: ACE2 ; Affinity ; Angiotensin ; Angiotensin-converting enzyme 2 ; Angiotensin-Converting Enzyme 2 - genetics ; Angiotensin-Converting Enzyme 2 - metabolism ; Animals ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Antibody Affinity ; Binding Sites, Antibody - immunology ; Camelids, New World ; COVID-19 ; COVID-19 - metabolism ; COVID-19 - therapy ; COVID-19 - virology ; Drug Discovery - methods ; Enzymes ; HEK293 Cells ; Humans ; Immunization - methods ; Inhalation ; Male ; Nanobodies ; Pandemics ; Peptidyl-dipeptidase A ; Protein Binding ; Protein Interaction Domains and Motifs - immunology ; Proteins ; SARS-CoV-2 - chemistry ; Severe acute respiratory syndrome coronavirus 2 ; Signal Transduction - genetics ; Single-Domain Antibodies - immunology ; Spike Glycoprotein, Coronavirus - chemistry ; Spike Glycoprotein, Coronavirus - genetics ; Spike protein ; Transduction, Genetic ; Transfection
Es parte de: Scientific reports, 2020-12, Vol.10 (1), p.22370-13, Article 22370
Descripción: There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12-15 kDa single-domain antibody fragments that can be delivered by inhalation and are amenable to relatively inexpensive large scale production compared to other biologicals. We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affinity. The lead nanobody candidate, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK293 cells expressing human ACE2 with an EC of 0.3 µg/mL. NIH-CoVnb-112 retains structural integrity and potency after nebulization. Furthermore, NIH-CoVnb-112 blocks interaction between ACE2 and several high affinity variant forms of the spike protein. These nanobodies and their derivatives have therapeutic, preventative, and diagnostic potential.
Editor: England: Nature Publishing Group
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 9 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L

England: Nature Publishing Group

Buscando en bases de datos remotas, por favor espere